CHICAGO — Trastuzumab deruxtecan significantly extended PFS and OS among patients with HER2-low metastatic breast cancer, regardless of hormone receptor status, compared with standard of care therapy.
Results of the phase 3 DESTINY-Breast04 trial, presented at ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine, additionally showed fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) exhibited a manageable safety profile.
“We currently define the HER2 status of breast cancers in a binary model where HER2 breast cancers driven by